The Patent Finder
AT

Arcturus Therapeutics, Inc.

First filing 2009
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Alcobra Ltd. (to 2018)

60 patents currently held

6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Sep 2028. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Sep 2028
Next term end
32
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Asymmetric Ionizable Cationic Lipid for RNA Delivery US 9,365,610
Cited by 38 later US patents, top 10% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ends no later than Nov 2034 · Medium confidence
Also notable
Hydroxymethyl Substituted RNA Oligonucleotides and RNA Complexes US 8,314,227
The most cited patent in this portfolio, cited by 51 later US patents, top 25% of utility patents granted in 2012 in our data. Protection runs to 2028.
Ends Sep 2028 · High confidence
Also notable
Ionizable Cationic Lipid for RNA Delivery US 10,383,952
Cited by 21 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Ends Dec 2036 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Dec 9 to 27, 2026 · next Dec 9
  • 3 fees due Feb 6 to 28, 2027 · next Feb 6
  • 4 fees due Mar 3 to 24, 2027 · next Mar 3
  • 1 fee due May 26, 2027
    The maintenance fee for Trinucleotide Mrna Cap Analogs (US 10,487,105) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
  • 1 fee due Jun 30, 2027
    The maintenance fee for Therapeutic Una Oligomers and Uses Thereof (US 10,519,447) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Jul 7, 2027
    The maintenance fee for Ionizable Cationic Lipid for RNA Delivery (US 10,526,284) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
  • 1 fee due Aug 11, 2027
    The maintenance fee for Ionizable Cationic Lipid for RNA Delivery (US 10,556,861) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
  • 4 fees due Sep 26 to 30, 2027 · next Sep 26
  • 1 fee due Nov 17, 2027
    The maintenance fee for Una Oligomer Structures for Therapeutic Agents (US 9,340,789) comes due Nov 17, 2027. Unpaid by May 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 23, 2026

What they patent

The largest of its 32 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,314,227Hydroxymethyl Substituted RNA Oligonucleotides and RNA Complexes
In force
 · High confidence
In forceHigh confidence
US 9,051,570Una Oligomers for Therapeutics
In force
 · High confidence
In forceHigh confidence
US 9,340,789Una Oligomer Structures for Therapeutic Agents
In force
 · High confidence
In forceHigh confidence
US 9,365,610Asymmetric Ionizable Cationic Lipid for RNA Delivery
In force
 · Medium confidence
In forceMedium confidence
US 9,580,711Lipid Particles with Asymmetric Cationic Lipids for RNA Delivery
In force
 · Medium confidence
In forceMedium confidence
US 9,670,152Ionizable Cationic Lipid for RNA Delivery
In force
 · High confidence
In forceHigh confidence
US 9,850,202Ionizable Cationic Lipid for RNA Delivery
In force
 · High confidence
In forceHigh confidence
US 9,896,413Ionizable Cationic Lipid for RNA Delivery
In force
 · High confidence
In forceHigh confidence
US 9,951,002Ionizable Cationic Lipid for RNA Delivery
In force
 · High confidence
In forceHigh confidence
US 10,399,937Ionizable Cationic Lipid for RNA Delivery
In force
 · High confidence
In forceHigh confidence
10 of 60 patents shown.
Pro members see all 60.
Pro members: see all 60 patents
Also on record, not counted in the 60: 6 patents in force now held by others · 4 patents ended · 31 applications pending · 11 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited